You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

BLOXIVERZ Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Bloxiverz, and when can generic versions of Bloxiverz launch?

Bloxiverz is a drug marketed by Exela Pharma and is included in one NDA.

The generic ingredient in BLOXIVERZ is neostigmine methylsulfate. There are nine drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the neostigmine methylsulfate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Bloxiverz

A generic version of BLOXIVERZ was approved as neostigmine methylsulfate by FRESENIUS KABI USA on January 8th, 2015.

  Try a Trial

Drug patent expirations by year for BLOXIVERZ
Drug Prices for BLOXIVERZ

See drug prices for BLOXIVERZ

Recent Clinical Trials for BLOXIVERZ

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of Missouri-ColumbiaPhase 4
Merck Sharp & Dohme LLCPhase 4

See all BLOXIVERZ clinical trials

Pharmacology for BLOXIVERZ

US Patents and Regulatory Information for BLOXIVERZ

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Exela Pharma BLOXIVERZ neostigmine methylsulfate SOLUTION;INTRAVENOUS 204078-001 May 31, 2013 AP RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Exela Pharma BLOXIVERZ neostigmine methylsulfate SOLUTION;INTRAVENOUS 204078-003 Oct 27, 2023 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Exela Pharma BLOXIVERZ neostigmine methylsulfate SOLUTION;INTRAVENOUS 204078-002 May 31, 2013 AP RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.